Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline2022년 6월 업데이트: 코로나바이러스 질병 2019(COVID-19)로 입원한 성인 관리: 유럽 호흡기 학회 생활 지침Editorial Published on 2022-08-102022-09-11 Journal: The European Respiratory Journal [Category] Fulltext, SARS, 바이오마커, [키워드] anti-IL-6 anticoagulation Baricitinib coronavirus disease Corticosteroids COVID-19 guideline European hospitalised hospitalised patient Hospitalised patients management monoclonal antibodies Non-invasive respiratory support recommendation respiratory Society with COVID-19 [DOI] 10.1183/13993003.00803-2022 PMC 바로가기 [Article Type] Editorial
Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade인터루킨-6 차단 후 중증 COVID-19에서 회복된 환자에서 SARS-CoV-2에 대한 강력한 장기 면역Article Published on 2022-08-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 바이오마커, 진단, 치료법, [키워드] 1:1 Affect anti-IL-6 anti-IL-6 therapy anti-IL6 antibody Antibody responses blockade conducted COVID-19 Critical deleterious effect deleterious effects domain Effect evaluated Follow-up greater humoral IgG IgG antibody IL-6 IL-6 blockade Immunity incidence increase in Infection interferon interferon-γ interleukin interleukin-6 Interleukin-6 blockade Laboratory longitudinal cohort study magnitude median Neutralizing antibodies neutralizing antibody no increase Patient patients hospitalized patients with COVID-19 positive proportion Prospective protective immunity receiving Reinfection responded to vaccination response responses risk robust SARS-CoV-2 SARS-COV-2 infection Seropositivity severe COVID-19 Spain subject subjects T-cell T-cell immunity T-cell Response T-cell responses therapy Tocilizumab treated [DOI] 10.1016/j.ebiom.2022.104153 PMC 바로가기 [Article Type] Article
Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID studyObservational Study Published on 2022-02-012022-10-05 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI Active surveillance acute respiratory distress adjusted age analysed Analysis anti-IL-6 association case report forms collected criteria death Dexamethasone discharge eligible participant enrolled Follow-up French fungal Fungal infection fungal pathogen groups hazard ratio high mortality high risk highlight ICU ICU admission ICUs identify IFI Infection intensive care intensive care unit invasive knowledge mechanical ventilation mechanically ventilated patient mechanically ventilated patients men microorganism Mortality Mucormycosis multicentre Multivariate analysis National Observational cohort study Odds ratio Older outcome Patient performed Pfizer Population Prevalence Primary outcome Registered regression models risk factor Risk factors SARS-COV-2 infection screened secondary severe COVID-19 significantly higher solid organ transplantation survival curve syndrome Treatment variable with COVID-19 [DOI] 10.1016/S2213-2600(21)00442-2 PMC 바로가기 [Article Type] Observational Study
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab토실리주맙에 불응성인 SARS-CoV-2와 관련된 중증 급성 호흡기 감염 치료의 잠재적인 대안으로서의 아나킨라Case Reports Published on 2021-12-012022-09-11 Journal: Reumatología clinica [Category] 진단, 치료제, [키워드] (Tocilizumab Acute respiratory infection Anakinra anti-IL-1 anti-IL-6 anti-IL-6 receptor anti-IL-6 treatment antibodies Antiviral Atypical Atypical pneumonia Case report cause Clinical outcome coronavirus disease Coronavirus disease 2019 COVID-19 cytokine Cytokine storm diagnosed dysregulation English haemophagocytic lymphohistiocytosis Health Organization IL-1 IL-6 immune system Inflammatory response multiorgan failure OMS Pandemia pandemic Pneumonia Produce receptor respiratory respiratory infection RNA virus SARS-CoV-2 severe respiratory infection Spanish Tocilizumab Tormenta de citoquinas. Treatment Trigger triggering triggers virus virus RNA WHO World Health Organization [DOI] 10.1016/j.reumae.2020.06.008 PMC 바로가기 [Article Type] Case Reports
Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic대유행의 첫 8개월 동안 15,000명 이상의 COVID-19 폐렴 환자에서 Tocilizumab 치료와 표준 치료에 대한 체계적인 검토 및 메타 분석Review Published on 2021-08-302022-09-12 Journal: International Journal of Environmental Research an [Category] SARS, 진단, [키워드] “cytokine storm” adjusted adopted Analysis anti-IL-6 anti-IL-6 therapy articles Bacterial infection Bacterial infections benefit case-control studies case-control study concomitant corticosteroid therapy controls Corticosteroid COVID-19 COVID-19 case Cytokine storm database death rate early stage early stages Effectiveness Efficacy eight estimate estimates heterogeneity ICU admission inception Infection lack management mechanical ventilation medRxiv Meta-analysis meta-regression Month mortality rate open label pandemic Patient performed Protective protective effect randomized trial reduction review robust SARS-CoV-2 virus SARS-CoV-2 virus infection severe COVID-19 SSRN Standard Standard of care steroid steroid use Subgroup analyses subgroup analysis subsequent suggested survival systematic review systematic review and meta-analysis therapeutic Tocilizumab Toxicity virus infection were assessed widespread [DOI] 10.3390/ijerph18179149 PMC 바로가기 [Article Type] Review
Diabetes Mellitus—A Risk Factor for Unfavourable Outcome in COVID-19 Patients—The Experience of an Infectious Diseases Regional HospitalArticle Published on 2021-06-232022-10-31 Journal: International journal for equity in health [Category] COVID-19, [키워드] administration anti-IL-6 antibody caused concerning connection COVID-19 Cytokine storm death diabete Diabetes Mellitus Diabetic diabetic patient diabetic patients diabetics diagnosed dysfunction Effect effective Effectiveness Evolution experience Factor form Frequency General population Glucose groups higher risk immune mechanism immunological implication Infection Infectious disease Inflammatory responses interstitial metabolism modulate monoclonal morbidity and mortality New coronavirus outcome Patient patients patients with diabete pulmonary disease Regional Research Respiratory failure risk Risk category SARS-COV-2 infection severity the disease therapy Treatment [DOI] 10.3390/healthcare9070788 PMC 바로가기 [Article Type] Article
Interleukin-6: obstacles to targeting a complex cytokine in critical illness인터루킨-6: 중환자에서 복잡한 사이토카인을 표적으로 하는 장애물Review Published on 2021-06-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] MERS, SARS, 바이오마커, 진단, [키워드] acute respiratory distress acute respiratory distress syndrome anti-IL-6 Anti-inflammatory approach approaches Biomarker Blood complex Concentration Critical Critical care cytokine disease effective Elevation elevations explain functions Health IL-6 IL-6 inhibition implication interleukin-6 Interpretation lung occur Patient physiological pleiotropic pro-inflammatory respiratory distress Sepsis serum Serum IL-6 severe COVID-19 syndrome therapeutic target Tocilizumab Treatment [DOI] 10.1016/S2213-2600(21)00103-X PMC 바로가기 [Article Type] Review
Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agentsReview Published on 2021-05-042022-10-29 Journal: Pediatric Rheumatology Online Journal [Category] COVID-19, [키워드] administration Adults Anakinra anti-IL-1 anti-IL-6 approach biologic agents canakinumab caused children Chloroquine clinical experience Colchicine condition contributing to coronavirus COVID-19 Cytokine storm defined develop disease course disease phenotype disease stage drug drugs dysregulation Evidence expression Hydroxychloroquine immune immune system impairment induce Inflammatory inflammatory mediator less macrophage activation syndrome manifestation Mild MIS-C multisystem inflammatory syndrome in children pediatric Pediatric patients pharmacological representing resulting role SARS-CoV-2 severe coronavirus disease severe disease supported syndrome systemic manifestation the disease the timing Therapeutic approach Tocilizumab Treatment [DOI] 10.1186/s12969-021-00559-5 PMC 바로가기 [Article Type] Review
The Rheumatology Drugs for COVID-19 Management: Which and When?Review Published on 2021-02-162022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] absence anti-IL-1 anti-IL-6 anti-IL-6 drugs anti-TNF antiviral therapy approach approved Baricitinib characterized Clinical management Clinical outcome Cochrane Library Colchicine Complication concerning Corticosteroids COVID-19 database drug hallmark HCQ heterogeneity hyperinflammatory status IL-2 IL-6 IL-7 IL-8 immunoglobulins immunomodulatory drug intravenous Necrosis neutralize patients patients with COVID-19 Pneumonia Result rheumatic disease SARS-CoV2 searched severe COVID-19 patients therapeutic strategy Treatment Vaccine while [DOI] 10.3390/jcm10040783 PMC 바로가기 [Article Type] Review
Fighting the storm: could novel anti-TNFα and anti-IL-6 C. sativa cultivars tame cytokine storm in COVID-19?폭풍과의 싸움: 새로운 항-TNFα 및 항-IL-6 C. sativa 품종이 COVID-19의 사이토카인 폭풍을 길들일 수 있습니까?Research Paper Published on 2021-01-312022-08-31 Journal: Aging (Albany NY) [Category] 치료제, [키워드] acute respiratory distress acute respiratory distress syndrome addition aging anti-IL-6 anti-inflammatory effect Anti-inflammatory effects anti-inflammatory regimen approach ARDS autoinflammatory disease Cancer cannabis cascade CCL2 cell line complications conditions COVID-19 COVID-19 cytokine storm COVID-19 disease COVID-19 patient COVID-19 patients COX2 cytokine Cytokine storm Cytokines death Deleterious disease disease severity down-regulation downregulate effective Escalation expression fibroblast fibrosis Fighting frailty Gene Expression had no IL-6 include induce Inflammation Inflammatory Inflammatory cytokine Initially involved lead leads lung Lung fibrosis medical cannabis modulate molecular MOST no effect novel Pathogenesis pathway Pathways Prevent pro-inflammatory cytokine pro-inflammatory cytokines proinflammatory cytokines respiratory distress responsible rheumatological SARS-CoV2 Seven severe COVID-19 disease syndrome target tested therapeutic These data tissue tissues TNFα TNFα treat treated Treatment [DOI] 10.18632/aging.202500 PMC 바로가기 [Article Type] Research Paper